Coherus Oncology, Inc.CHRSNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -5.09% | -40.84% | +229.25% | -84.22% | -83.65% |
| Gross Profit Growth | +19.51% | +191.59% | +469.16% | -80.64% | -84.31% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | -154.99% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | -153.85% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | -159.76% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +17.88% | +3.52% | +2.76% | +1.10% | +0.88% |
| Weighted Average Shares Diluted Growth | +17.88% | +3.52% | -7.71% | +1.10% | +0.88% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | -178.07% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | -178.07% | +0.00% |
| Receivables Growth | -8.18% | -53.04% | -78.03% | -61.85% | +26.00% |
| Inventory Growth | -28.66% | +11.96% | -94.32% | -92.74% | -95.70% |
| Asset Growth | -13.50% | -28.76% | -51.40% | -34.88% | +2.28% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -43.62% | -43.87% | -43.90% | -86.25% | -84.92% |
| R&D Expense Growth | -15.48% | -19.47% | -14.31% | +26.67% | +25.72% |
| SG&A Expenses Growth | -27.95% | -16.56% | -35.31% | -25.95% | -34.29% |